Expertise in
2
conditions

Dr. Thomas Chauncey

Oncology
VA Puget Sound Healthcare System
1660 S Columbian Way, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
2
conditions
VA Puget Sound Healthcare System
1660 S Columbian Way, 
Seattle, WA 

Overview

Thomas Chauncey is an Oncologist in Seattle, Washington. Dr. Chauncey is highly rated in 2 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Leukemia, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Premera
  • EPO
  • PPO

Locations

VA Puget Sound Healthcare System
1660 S Columbian Way, Seattle, WA 98108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug, Other, Procedure, Radiation
Study Drugs: Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Thiotepa
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Terminated
Publish Date: January 23, 2023
Intervention Type: Drug, Biological, Radiation, Procedure
Study Drugs: Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Enrollment Status: Completed
Publish Date: April 16, 2020
Intervention Type: Drug, Procedure, Radiation, Other
Study Phase: Phase 2
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Radiation, Procedure, Drug, Other
Study Phase: Phase 2
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug, Radiation, Other, Procedure
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.
Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (4.5 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is highly rated in 23 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma.

Expertise in
19
conditions
Dr. John Pagel
Oncology
Expertise in
19
conditions
Dr. John Pagel
Oncology

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (2.9 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances

John Pagel is an Oncologist in Seattle, Washington. Dr. Pagel is highly rated in 19 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Bart Scott
Oncology
Expertise in
13
conditions
Dr. Bart Scott
Oncology

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (6.0 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bart Scott is an Oncologist in Seattle, Washington. Dr. Scott is highly rated in 13 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Thomas Chauncey

How do I make an appointment with Dr. Thomas Chauncey?

You can book an appointment with Dr. Thomas Chauncey by calling their office at 206-762-1010. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Chauncey a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Chauncey is classified as an Advanced expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Chauncey specialize in?

While Dr. Thomas Chauncey is a Oncology, they have specific expertise in Mantle Cell Lymphoma (MCL), Leukemia, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Thomas Chauncey participate in research or clinical trials?

Yes. Dr. Thomas Chauncey has published 48 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Thomas Chauncey's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas Chauncey accept my insurance?

Dr. Thomas Chauncey accepts most major insurance plans, including Premera. We recommend calling the office directly at 206-762-1010 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chauncey's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile